PROCTER & GAMBLE HEALTH L
PGHL · General/Diversified · NSE
₹6,208
Current Market Price
Fair Value (DCF)
₹4,171
Discount to FV
-32.8%
Updated just now
YieldIQ Score
50/100
Piotroski F-Score
7/9
Economic Moat
Wide
Confidence
68%
ROE
3.1%
Debt/Equity
0.01
WACC
11.1%
Market Cap
₹10,305 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
4.3%
Return on capital employed
EV / EBITDA
22.7×
Enterprise multiple
Debt / EBITDA
0.0×
Leverage vs earnings
Interest Coverage
380.6×
EBIT covers interest
Current Ratio
2.39×
Short-term liquidity
Asset Turnover
1.77×
Revenue per ₹ of assets
Revenue CAGR (3Y)
8.8%
3-year revenue growth
Revenue CAGR (5Y)
—
5-year revenue growth
DCF Scenario Analysis
vs CMP ₹6,208
Bear case
Discount -172.1%
Base case
Discount -48.8%
Bull case
Discount -24.0%
Ratio Trends
PGHL · last 5 annual periods
ROE
3.1%
ROCE
4.3%
Operating Margin
—
Debt / Equity
—
PE
270.5×
EV / EBITDA
22.2×
Historical Financials
PGHL · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2021 NSE_XBRL | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹991 Cr | ₹1092 Cr | ₹1206 Cr | ₹1129 Cr | ₹1408 Cr | +9.2% |
| EBITDA | ₹264 Cr | ₹281 Cr | ₹343 Cr | ₹301 Cr | ₹474 Cr | +15.7% |
| EBIT | ₹234 Cr | ₹254 Cr | ₹315 Cr | ₹274 Cr | — | +4.0% |
| PAT | ₹177 Cr | ₹193 Cr | ₹229 Cr | ₹201 Cr | ₹327 Cr | +16.6% |
| EPS (diluted) | ₹106.50 | ₹116.00 | ₹138.23 | ₹121.07 | — | +3.3% |
| CFO | ₹247 Cr | ₹170 Cr | ₹236 Cr | ₹228 Cr | ₹338 Cr | +8.1% |
| CapEx | ₹-52.6 Cr | ₹-37.9 Cr | ₹-42.5 Cr | ₹-21.7 Cr | ₹-15.5 Cr | — |
| FCF | ₹195 Cr | ₹132 Cr | ₹194 Cr | ₹207 Cr | ₹322 Cr | +13.4% |
| Total Assets | ₹986 Cr | ₹888 Cr | ₹1101 Cr | ₹794 Cr | ₹841 Cr | -3.9% |
| Total Debt | ₹7.6 Cr | ₹2.8 Cr | ₹12.0 Cr | ₹9.6 Cr | ₹9.3 Cr | +5.1% |
| Shareholders' Equity | ₹704 Cr | ₹616 Cr | ₹751 Cr | ₹538 Cr | ₹525 Cr | -7.1% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
PGHL vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
 AKUMS AKUMS | — | — | Pending | 7.7% | — |
 SHILPAMED SHILPAMED | — | — | Pending | 3.3% | — |
VIYASH VIYASH | — | — | Pending | 2.8% | — |
 STAR STAR | — | — | Pending | 138.9% | — |
SUDEEPPHRM SUDEEPPHRM | — | — | Pending | 28.1% | — |
Click a ticker to view its fair-value analysis.
Dividend History
15 ex-dividend events on file. Source: NSE corporate-actions feed.
Total paid (5Y)
₹822.50/sh
Last payout
2026-02-12
₹160.00
Peak payout
₹440.00
Trailing yield
3.30%
Amounts parsed from NSE subject lines. Percent-of-face-value declarations are converted using the per-ticker face value (defaults to ₹10).
AI Analysis Summary
Model-generated description of metrics. Not investment advice. PROCTER & GAMBLE HEALTH L (PGHL.NS) trades at 6208.00 vs a model fair value of 4171.45, a gap of -32.8%. Piotroski F-score: 7/9. Moat lab...
Read full AI analysis →Reverse DCF
Market-implied growth
What FCF growth is priced in →
Risk Analysis
Volatility & drawdown
Risk profile of PGHL →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for PGHL →
Compare
Head-to-head with peers
Compare PGHL side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse PGHLNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.